Table 1.
Demographic characteristics of patients prior to Levosimendan treatment.
| Demographic characteristics | Single dose n=16 | Repeated n=13 | p |
|---|---|---|---|
| Age (year) | 59.6±7.2 | 60.8±7.9 | 0.72 |
| Gender (female/male) | 6/10 | 3/10 | 0.41 |
| Heart rate (pulse/min) | 85.5±5.8 | 85.5±6.7 | 0.86 |
| Functional capasity (NYHA: III/IV) | 5/11 | 4/9 | 0.81 |
| Systolic blood pressure (mm Hg) | 106.5±8.5 | 105.7±8.6 | 0.72 |
| Diastolic blood pressure (mm Hg) | 70.9±8.2 | 72.3±8.5 | 0.48 |
| Diabetes mellitus (%) | 6 (37.5) | 4 (30.8) | 0.68 |
| Hypertension (%) | 8 (50.0) | 9 (69.2) | 0.23 |
| Smoking (%) | 5 (31.3) | 8 (61.5) | 0.22 |
| Body surface area (m2) | 1.8±0.16 | 1.8±0.14 | 0.87 |
| Body mass index (kg/m2) | 23.8±2.0 | 24.1±3.6 | 0.71 |
| Digoxin (%) | 11 (68) | 8 (62) | 0.82 |
| ACE inhibitor (%) | 16 (100) | 13 (100) | 1.00 |
| Diuretic (%) | 16 (100) | 13 (100) | 1.00 |
| Statin (%) | 16 (100) | 13 (100) | 1.00 |
| Amiodarone (%) | 3 (18) | 2 (15) | 0.81 |
LS – levosimendan, NYHA – New York Heart Association.